Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 17/20 | 0.43 |
| ▸ | PYGM | P11217 | 14/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4800991 | 1.00 | PYGL (0.43) | PYGLPYGMLMNAAADAT | |
| SCHEMBL14193208 | 0.89 | PYGL (0.43) | PYGLPYGMAADAT | |
| SCHEMBL4799822 | 0.86 | MTNR1A (0.49) | PYGLPYGM | |
| SCHEMBL4799807 | 0.86 | MTNR1A (0.49) | PYGLPYGM | |
| SCHEMBL3786087 | 0.84 | PYGL (0.40) | PYGLPYGM | |
| SCHEMBL14193205 | 0.83 | SLC6A2 (0.50) | PYGLPYGMAADAT | |
| SCHEMBL3785883 | 0.80 | AADAT (0.56) | PYGLPYGMAADAT | |
| SCHEMBL20028018 | 0.78 | RAB9A (0.47) | PYGLPYGM | |
| SCHEMBL25329972 | 0.76 | OPRM1 (0.45) | PYGLPYGMLMNA | |
| SCHEMBL9288876 | 0.75 | MMP1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE40278-E1 | Heterocyclic amines having central nervous system activity | PHARMACIA & UPJOHN COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| US-7074927-B2 | Heterocyclic amines having central nervous system activity | PHARMACIA & UPJOHN COMPANY (US) | 2006-07-11 | — | — | US | disclosed |
| US-20050107378-A1 | Heterocyclic amines having central nervous system activity | ROMERO ARTHUR G (US) | 2005-05-19 | — | — | US | disclosed |
| US-RE38452-E1 | SUITABLE FOR TREATING ANXIOLYTIC DISORDER, SCHIZOPHRENIA, PARKINSON'S DISEASE, ANXIETY | PHARMACIA & UPJOHN COMPANY | 2004-03-02 | — | — | US | disclosed |
| US-20020187981-A1 | Heterocyclic amines having central nervous system activity | ROMERO ARTHUR GLENN (US) | 2002-12-12 | — | — | US | disclosed |
| US-20010009916-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | ROMERO ARTHUR G (US) | 2001-07-26 | — | — | US | disclosed |
| EP-0724584-B1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | UPJOHN CO (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5652245-A | Heterocyclic amines having central nervous system activity | PHARMACIA & UPJOHN COMPANY (US) | 1997-07-29 | — | — | US | disclosed |
| EP-0724584-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995004056-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009916-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | CNR1, CNR2, OPRD1 | PYGL 3299/4885PYGM 3678/4885LMNA 1692/4885 |
| US-20020187981-A1 | Heterocyclic amines having central nervous system activity | CNR1, CNR2, OPRD1 | PYGL 3290/4885PYGM 3684/4885LMNA 1718/4885 |
| US-20050107378-A1 | Heterocyclic amines having central nervous system activity | CNR1, CNR2, NPY2R | PYGL 3968/4885PYGM 3803/4885LMNA 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.